Evolent Health, Inc.

NYSE•EVH

CEO: Mr. Seth Barrie Blackley

セクター: Healthcare

業種: Medical - Healthcare Information Services

上場日: 2015-06-05

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

連絡先情報

1812 N. Moore Street, Suite 1705, Arlington, VA, 22209, United States

571-389-6000

www.evolent.com

時価総額

$337.15M

PER (TTM)

-0.6

29.9

配当利回り

52週高値

$12.07

52週安値

$2.50

52週レンジ

順位53Top 76.1%

2.8

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$468.72M+0.00%

直近4四半期の推移

EPS

-$3.76+0.00%

直近4四半期の推移

フリーCF

$41.04M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Drops 26.6% Total revenue decreased $678.5 M USD to $1.88 B USD, driven by Performance Suite customer transitions and scope narrowing.

Cost of Revenue Improves Cost of revenue fell 32.5% to $1.48 B USD, primarily due to $715.7 M USD lower claims cost from scope shifts.

Significant Goodwill Impairment Recorded $398.0 M USD non-cash goodwill impairment charge following prolonged stock price decline below carrying value assessment.

Ending Cash Position Cash and restricted cash totaled $180.7 M USD as of December 31, 2025, sufficient for next twelve months operations.

リスク要因

High Partner Revenue Concentration Significant portion of revenue derived from largest partners; loss or renegotiation of contracts could severely impact financial results.

Operating Loss Widens Sharply Operating loss increased 913.1% to $(410.1 M) USD in 2025, reflecting revenue drop and significant goodwill charge recorded.

Debt Covenants Limit Flexibility $934.0 M USD principal debt outstanding subjects operations to restrictive covenants, limiting financing flexibility and growth funding.

Ongoing Regulatory Scrutiny Risks Subject to audits by CMS and governmental payers, including ongoing False Claims Act investigation impacting reputation and potential loss.

見通し

Growth via Embedded Expansion Expect growth through expanding lives in existing populations, cross-selling solutions, and capturing value via new risk-sharing arrangements.

Scale Reduces Cost Percentage Expect centralized resource investment to decrease as percentage of revenue by scaling investment across broader group of partners.

Invest in Proprietary Technology Continue investing in proprietary technology like Identifi® to enhance clinical processes, scale value-based services, and capitalize on payment relationships.

Selectively Pursue Acquisitions Will pursue acquisition and investment opportunities of niche vendors or complementary businesses to expand breadth of offerings.

同業比較

売上高 (TTM)

AMN

$2.73B

-8.5%

EVH

$1.88B

-26.6%

TNDM

$1.01B

-4.2%

粗利益率 (最新四半期)

ANAB

199.8%

+99.5pp

KURA

97.3%

+0.0pp

XNCR

90.9%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ANAB	$1.86B	-135.8	1813.8%	79.8%
TNDM	$1.51B	-7.4	-142.0%	64.0%
EYPT	$1.24B	-5.3	-88.3%	5.7%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-1.0%

横ばい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月6日

EPS:-$0.05

売上高:$534.04M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし